Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole with or without Zoledronic acid as extended adjuvant therapy in postmenopausal primary breast cancer
2004-003888-71Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of letrozole and zoledronic acid in breast cancer and osteoporosis (2 arms), sponsored by Novartis. Started May 2006; status: completed.
02
Drugs
letrozolezoledronic acid
03
Conditions
breast cancerosteoporosis
Beyond the preview
Go deeper on 2004-003888-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003888-71.